Statement of Principles concerning essential thrombocythaemia (Reasonable Hypothesis) (No. 91 of 2021)

This instrument is a Statement of Principles (SoP) concerning essential thrombocythaemia (ET) issued by the Repatriation Medical Authority, numbered No. 91 of 2021. It is made under subsection 196B(2) of the Veterans' Entitlements Act 1986, it was dated 20 August 2021, and it commences on 20 September 2021 (see ss 1-3). It expressly repeals the prior Statement of Principles concerning essential thrombocythaemia No. 15 of 2013 (s 4).

Mechanically, the SoP performs the statutory task of setting out the medical definition of the disease for the purposes of claims under the veterans’ compensation and rehabilitation schemes and prescribing the specific factors that must be present before a reasonable hypothesis can be said to link ET, or death from ET, with relevant service. It applies to claims to which section 120A of the Veterans’ Entitlements Act 1986 (VEA) or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) applies (s 5). The RMA records the evidential basis for issuing the SoP in section 8, stating that there is sound medical‑scientific evidence indicating ET and death from ET can be related to relevant service rendered by veterans and members under the VEA and MRCA (s 8).

Substantively the SoP does three things. First, it sets a statutory meaning of essential thrombocythaemia for these claim purposes (s 7(2)), including several clinical notes which the instrument itself supplies (Notes 1-3 to s 7). Second, it identifies the specific causal factors that must exist before a reasonable hypothesis is raised: (a) a tobacco smoking exposure threshold quantified by pack‑years and timing conditions, and (b) inability to obtain appropriate clinical management for ET (s 9). Third, it states how those factors must relate to relevant service, including a limitation that the management factor at s 9(2) applies only where the ET pre‑existed or was contracted before or during but did not arise out of the relevant service and addresses material contribution or aggravation (s 10(2)).

The SoP also addresses classification issues. It notes that although ET attracts ICD‑10‑AM code D47.3, the statutory meaning for claims is that given in s 7(2) and therefore is not determined solely by the ICD code (ss 7(3)-(4)). For death claims, the SoP treats ET as including death from a terminal event or condition that was contributed to by the person’s ET, and it defines “terminal event” in the Schedule (s 7(5), Schedule). The Schedule supplies key definitions used across the instrument, including one pack‑year and relevant service categories.

The instrument is not a statute of entitlements itself, rather it is a medical causation instrument to be applied to claims under VEA and MRCA provisions. It neither creates new penalties nor prescribes payments; it sets out the medical criteria that decision‑makers are to apply when assessing whether a reasonable hypothesis connects ET, or death from ET, with relevant service (ss 3, 5, 8-11).

The core legal concepts in this Statement of Principles are the statutory disease definition, the list of causal factors that must exist to raise a reasonable hypothesis, the temporal and causal relationship of those factors to relevant service, and cross‑references to other SoPs where factors refer to other injuries or diseases. The RMA’s statutory authority to issue such a statement is recorded at s 3, and s 8 explains that the RMA considers there is sound medical‑scientific evidence linking ET and death from ET to relevant service.

Meaning of essential thrombocythaemia, as provided in s 7(2), is a tightly phrased medical description: a chronic, Philadelphia‑chromosome negative myeloproliferative neoplasm characterised by bone marrow megakaryocytic proliferation, resulting in excessive, clonal platelet production and marked thrombocytosis in peripheral blood. The instrument also expressly excludes secondary or reactive thrombocytosis (s 7(2)(b)). The instrument adds clinical notes (Note 1 lists typical manifestations; Note 2 describes potential disease course; Note 3 lists causes of secondary thrombocytosis), which inform the medical understanding for claim assessment but do not alter the statutory definition.

The instrument’s causal threshold for a “reasonable hypothesis” is exercised through an explicit, minimal set of factors in section 9. The first factor is a detailed smoking metric: at least 10 pack‑years before clinical onset of ET, commencement of smoking at least 5 years before clinical onset, and if smoking ceased before clinical onset, that onset must have occurred within 15 years of cessation (s 9(1)). The Schedule defines one pack‑year and explains how to calculate pack‑years, including equivalence values for non‑cigarette tobacco (Schedule, definition of one pack‑year and Note 1 and Note 2). The second factor is inability to obtain appropriate clinical management for ET (s 9(2)). Section 10(2) constraints that management factor to cases where ET was suffered or contracted before or during relevant service, but did not arise out of the relevant service, and where inability to obtain appropriate clinical management materially contributed to, or aggravated, the ET.

The instrument also provides interaction rules. Section 11 sets out that if a factor in s 9 refers to an injury or disease covered by another SoP, the factors in that other SoP apply according to its terms as in force. Section 7(3) and (4) address the relationship between the statutory definition and the ICD‑10‑AM classification, stating that even though ET attracts code D47.3, the meaning for applying the SoP is the statutory meaning in s 7(2), and the ICD‑10‑AM citation is specified by edition and effective date (s 7(4)).

This SoP affects persons making claims under the VEA or MRCA provisions specified at s 5, namely claims to which section 120A of the VEA or section 338 of the MRCA applies. The instrument identifies the RMA’s view that ET and death from ET can be related to relevant service by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA (s 8). The Schedule further defines “relevant service” to include operational, peacekeeping, hazardous and British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA (Schedule, definition of relevant service).

Primary affected actors are therefore claimants who assert that ET or death from ET was connected to their relevant service, and the decision‑making bodies and medical assessors who must apply the SoP when determining whether a reasonable hypothesis exists. The SoP constrains the medical causation question by prescribing the factors that must be present before the causal connection is accepted as reasonably hypothesised (s 9). Because the SoP can operate as a determinative criterion for the precondition of a claim, its content directly affects whether a claimant will pass the threshold for further consideration under the VEA or MRCA processes.

Medical practitioners producing reports for claims are affected in that their opinions and the evidence they provide must engage explicitly with the definitions and factors set in the SoP. For example, clinicians should address whether the person meets the pack‑year threshold and the timing requirements in s 9(1), or whether there was inability to obtain appropriate clinical management in circumstances contemplated by s 9(2) and s 10(2). The Schedule’s definition of one pack‑year and its examples provide a numerical method for clinicians and advocates to translate reported tobacco use into the statutory metric.

Administrators and decision‑makers processing claims are affected in two respects. First, they must apply the SoP’s definition of ET (s 7(2)) rather than relying solely on ICD‑10‑AM codes, even though the instrument notes the ICD code for ET (ss 7(3)-(4)). Second, they must consider whether factors in s 9 are present and whether they are related to the person’s relevant service as required by s 10(1) and (2).

Finally, because the SoP contains linkage rules to other Statements of Principles (s 11), claimants whose causal factors reference other diseases will be affected by the content and status of those other SoPs. The instrument states that, where a factor refers to an injury or disease covered by another SoP, the factors in that other SoP apply in accordance with its terms as in force from time to time (s 11). Consequently, changes to other SoPs may indirectly affect ET claims where cross‑referenced factors are invoked.

This instrument does not itself impose civil duties or criminal sanctions. Instead, it prescribes the medical criteria that must be satisfied for a reasonable hypothesis connecting ET or death from ET to relevant service. Those criteria function as rights and conditions in the context of entitlement determinations under the VEA and MRCA.

Key legal requirements for claimants. The SoP requires, as a minimum, that at least one of the factors set out in s 9 be present before a reasonable hypothesis can be raised linking ET (or death from ET) with service. The smoking factor at s 9(1) imposes three concurrent requirements: a quantitative exposure of at least 10 pack‑years, commencement at least 5 years before clinical onset, and if smoking ceased prior to clinical onset that the clinical onset occurred within 15 years of cessation. The Schedule provides the metric for calculating one pack‑year and examples, including conversion for pipe tobacco and cigars (Schedule, one pack‑year, Notes 1 and 2). These statutory thresholds function as evidentiary gates; absent evidence satisfying them, the smoking factor cannot be counted to raise a reasonable hypothesis.

The second listed factor, inability to obtain appropriate clinical management for ET (s 9(2)), is phrased qualitatively. Section 10(2) places an additional temporal and causal qualification on that factor: it applies only to material contribution to, or aggravation of, ET where the person’s ET was suffered or contracted before or during the person’s relevant service, but did not arise out of the person’s relevant service. Consequently, for the management factor to assist a claimant, the ET must pre‑exist or be contracted before/during service and the inability to obtain appropriate management must have materially contributed to or aggravated the condition.

Decision‑maker obligations. Decision‑makers applying the SoP must identify whether the statutory disease definition is met (s 7(2)), whether a listed factor exists (s 9), and whether that factor is related to relevant service (s 10). The SoP directs that, when a factor refers to an injury or disease covered by another SoP, the factors in that other SoP apply according to its terms (s 11). The instrument does not specify how decision‑makers should weigh competing medical evidence or how to address uncertainty beyond the “reasonable hypothesis” standard, but it sets the minimum factual predicates for raising that hypothesis.

Rights for claimants and evidentiary implications. Claimants have the right to have their claims assessed with reference to the SoP once their claim falls within the VEA or MRCA provisions identified at s 5. Practically, they are entitled to rely on the quantitative definitions in the Schedule to demonstrate that a smoking history meets the statutory thresholds. For death claims, the SoP extends ET to include death from terminal events that were contributed to by the person’s ET (s 7(5), Schedule definition of terminal event), so executors or dependants asserting death‑based claims may rely on that articulation when presenting medical evidence.

The Statement of Principles does not create criminal offences, civil penalties, or a separate enforcement regime. It is a medical causation instrument made under subsection 196B(2) of the VEA to be applied in administrative entitlement determinations. The instrument does not prescribe enforcement mechanisms or sanctions; it sets medical criteria that are relevant to decisions under the VEA and MRCA (ss 3, 5, 8-11).

Consequential administrative effects. The practical effect is that the presence or absence of the factors in s 9 can determine whether a claimant reaches the “reasonable hypothesis” threshold that is a precondition for further consideration under the specified claim provisions. In that sense, the SoP has regulatory force through its function in eligibility assessments. If a decision‑maker applies the SoP and finds that no factor in s 9 exists or that the required relationship to relevant service is absent under s 10, the claim may be rejected or not proceed to further benefit assessment. Conversely, satisfying the SoP can enable a claim to proceed, potentially leading to benefits under the VEA or MRCA processes. The SoP itself does not specify remedies for incorrect application; those remedies would exist, if at all, under the procedural and merits review mechanisms in the VEA or MRCA frameworks, which are not reproduced in this instrument.

Discretion and administrative risk. The SoP contains elements that require evaluative judgments by clinicians and administrators, such as whether the clinical onset has occurred at a particular date, whether clinical management was “appropriate”, and whether lack of such management materially contributed to or aggravated ET (s 9(2), s 10(2)). Because the instrument does not define “clinical onset” or “appropriate clinical management”, these points will be matters for evidentiary assessment and administrative discretion. Disagreement on these questions may give rise to administrative review processes under the VEA or MRCA, and potentially to judicial review of administrative decisions, but the instrument itself does not set out enforcement or appeal mechanics.

Record accuracy and consequences. The Schedule provides numerical definitions for pack‑years and equivalence metrics for tobacco products (Schedule, one pack‑year and Notes 1-2). Inaccurate or incomplete records of tobacco consumption, clinical onset timing, or clinical management history can impede a claimant’s ability to satisfy the SoP’s factors. The instrument does not describe evidentiary standards or penalties for false statements; those matters are governed by the principal legislation and administrative processes to which this SoP applies.

This SoP is expressly created under the authority of subsection 196B(2) of the Veterans’ Entitlements Act 1986 (s 3). It is not itself a benefits statute; it provides medical causation criteria to be applied to claims under the VEA and the MRCA. Section 5 specifies that the instrument applies to claims to which s 120A of the VEA or s 338 of the MRCA applies. The instrument therefore interacts with the VEA and MRCA by supplying the medical link that decision‑makers use when assessing claims falling within those statutory provisions.

Cross‑references to other Statements of Principles appear at s 11. If a factor in s 9 refers to an injury or disease for which another SoP exists, the factors in that other SoP apply in accordance with its terms as in force at the relevant time (s 11). That mechanism creates direct legal interdependence between this SoP and other SoPs, meaning changes to other SoPs can affect the operation of this instrument where factors overlap or refer across instruments.

The SoP also interacts with medical classification systems by reference. Section 7(3) notes that ET attracts ICD‑10‑AM code D47.3, but s 7(3) and (4) make clear that for the purposes of applying the SoP the statutory definition in s 7(2) controls. Section 7(4) also fixes the version of ICD‑10‑AM that is referenced, by edition and effective date. The interplay means that codified clinical classifications inform but do not supplant the statutory definition.

Definitions in the Schedule tie the instrument to the VEA and MRCA frameworks. “Relevant service” is defined by reference to VEA and MRCA categories (Schedule, relevant service). The Schedule defines “terminal event” for death claims and gives the definition of one pack‑year used in s 9(1). These definitional cross‑links determine how factual evidence is transformed into conclusions under the VEA and MRCA.

The instrument repeals the earlier SoP No. 15 of 2013 (s 4). It does not itself state transitional arrangements or how prior assessments are to be treated. Consequently, its interaction with prior administrative decisions and pending claims is a procedural matter handled within the VEA and MRCA systems, not by the text of this SoP.

Finally, the SoP’s scope and application are bounded by the VEA and MRCA provisions referenced. Because the instrument does not set out the entitlement criteria, review rights, or payment mechanisms conferred by the VEA or MRCA, its practical legal effects must be understood in the context of those statutes and their administrative processes. The SoP supplies medical criteria for causation, but the application of those criteria, and any legal consequences that follow, are determined by the operative provisions of the VEA and the MRCA.

The instrument contains its own limited amendment record. It is identified as the Statement of Principles concerning essential thrombocythaemia (Reasonable Hypothesis) No. 91 of 2021 (s 1). It is dated 20 August 2021 and commences on 20 September 2021 (ss 1-2). Section 4 expressly repeals the prior Statement of Principles concerning essential thrombocythaemia No. 15 of 2013 (Federal Register of Legislation No. F2013L00409). The instrument does not record any other amendments, prior versions, or in‑text amendment clauses.

The Schedule specifies the edition and effective date of the ICD‑10‑AM classification that is cited (the Tenth Edition, effective date 1 July 2017), which anchors that external reference in time (s 7(4)). No later edition or alternative coding scheme is referenced in the instrument.

Because the instrument is an SoP made under s 196B(2) of the VEA, future amendments or replacements would be made by the Repatriation Medical Authority under the same statutory power. The instrument itself does not contain a clause dealing with transitional arrangements, saving provisions for decisions made under the repealed 2013 SoP, or retrospective application. It therefore records only the immediate change replacing the 2013 instrument with the 2021 instrument and the dates of making and commencement (ss 1-4). Any further amendment history will be recorded in subsequent replacements or in the Federal Register of Legislation, but those subsequent documents are not contained within this instrument.

Practitioners should note that the Schedule’s definitional details, including the one pack‑year equivalence values, form part of the operative text and are thus part of the amendment history insofar as they can be changed by a future SoP replacing this instrument. The instrument’s explicit repeal of the 2013 SoP means that, from the commencement date forward, assessments relying on the 2013 instrument should be supplanted by the 2021 instrument unless an administrative practice or law outside the text provides otherwise. The instrument itself does not state how pending claims at the time of repeal are to be handled.

This instrument contains no statement of judicial decisions, appeals, or litigation history. The text does not reference any court or tribunal determinations, nor does it cite any cases. It records administrative facts only: the date of making, commencement date, and the RMA Chairperson’s direction for affixing the Common Seal.

Although the instrument does not record litigation outcomes, the content of the SoP brings into focus several categories of legal contestability that could give rise to disputes in administrative or judicial forums. Those potential areas of disagreement can be identified directly from the instrument’s terms. For example, the SoP uses several concepts that are not expressly defined in the instrument, and those undefined terms are plausibly susceptible to different factual and legal interpretations, producing grounds for contestation in administrative review or judicial proceedings. The instrument requires, for the smoking factor, proof of “clinical onset” of ET, but does not define “clinical onset” (see s 9(1)). Similarly, the management factor refers to “inability to obtain appropriate clinical management” and to material contribution or aggravation, but does not define what constitutes appropriate management or the standard for material contribution (s 9(2); s 10(2)). Those textual gaps are focal points at which claimants, clinicians, and decision‑makers may disagree.

Another potential source of dispute the instrument itself highlights is measurement of tobacco exposure. The Schedule defines one pack‑year and gives equivalence measures (Schedule, one pack‑year, Notes 1 and 2), but factual disputes can arise over reliability of smoking histories, conversion of tobacco weights to cigarettes, and the dating of commencement and cessation relative to clinical onset (s 9(1)). The instrument’s heavy reliance on these quantitative thresholds makes the accuracy and admissibility of such evidence likely topics of contention.

Finally, the cross‑reference mechanism at s 11, which binds the factors in other SoPs where relevant, can produce disputes over which SoP applied at the relevant time, how to reconcile overlapping factors between SoPs, and how changes to other SoPs affect current assessments. While the instrument itself does not report any litigation, its substantive terms create identifiable avenues where administrative decisions applying the SoP may be challenged through the review processes provided in the VEA and MRCA frameworks.

Because the instrument itself contains no litigation record, readers seeking actual case outcomes or judicial interpretations of the 2021 SoP must consult administrative decisions and courts’ records outside this document. The instrument supplies the textual points likely to be litigated, but does not enumerate any decisions or case law.

This SoP contains several textual and practical features that can produce traps for practitioners, claimants, and decision‑makers. These are matters of textual design and evidentiary mechanics that follow directly from the instrument’s wording.

1. Quantitative smoking thresholds are cumulative and timing‑sensitive, not optional. Section 9(1) lists three conjunctive requirements: at least 10 pack‑years before clinical onset, commencement at least 5 years before clinical onset, and if smoking ceased before onset, the onset must have been within 15 years of cessation. All three elements must be satisfied to rely on the smoking factor. Practitioners should not assume meeting the 10 pack‑year total alone suffices.

2. Pack‑year calculation specifics are in the Schedule, not in s 9. The Schedule defines one pack‑year as smoking 20 cigarettes per day for one year, and supplies equivalence values for non‑cigarette tobacco and an example method for calculation (Schedule, Notes 1-2). For pipe tobacco and cigars, the instrument equates 1 gram of tobacco to one cigarette and gives 7,300 grams per year as the equivalent of 20 cigarettes per day. That numeric equivalence is part of the operative text. Failure to convert non‑cigarette tobacco into the statutory equivalence correctly can cause erroneous conclusions about whether the threshold is met.

3. “Clinical onset” is not defined in the instrument. Section 9 invokes the concept of clinical onset as the temporal reference for the smoking thresholds, but the instrument does not specify how clinical onset is to be established. That creates practical risk, because onset dating will often depend on medical records, symptom history, and diagnostic testing. Decision‑makers and clinicians must therefore pay careful attention to how they characterise onset in medical reports.

4. “Inability to obtain appropriate clinical management” is undefined and temporally constrained. The management factor in s 9(2) is not given a definition of “appropriate clinical management”. Section 10(2) further confines the management factor to cases where ET was suffered or contracted before or during service and did not arise out of service, and where lack of management materially contributed or aggravated the ET. Practitioners should not treat s 9(2) as a general causation ground; it is a narrowly framed aggravation/material contribution mechanism with temporal limits.

5. ICD code is informative but not determinative. The SoP states that ET attracts ICD‑10‑AM code D47.3 but that, for the purpose of applying the SoP, the meaning is the definition in s 7(2) (ss 7(3)-(4)). A claimant with records listing the ICD code still needs evidence that the clinical and pathological features match the statutory definition, and clinicians should link their reports to the statutory features in s 7(2), not rely solely on certification or coding.

Compliance, in this context, means preparing and presenting claims and medical evidence so decision‑makers applying this SoP can conclude that at least one of the s 9 factors exists and that it relates to the claimant’s relevant service as required by s 10. The following practical steps follow directly from the text of the instrument.

1. Confirm the claim falls to the relevant statutory pathway. Before relying on this SoP, confirm that the claim is “to which section 120A of the VEA or section 338 of the MRCA applies” (s 5). The SoP only governs causation questions for those claim types.

2. Align medical definitions to the statutory wording. Where medical reports diagnose ET, ensure the report explicitly addresses the statutory definition in s 7(2): evidence of a chronic, Philadelphia‑chromosome negative myeloproliferative neoplasm, bone marrow megakaryocytic proliferation, clonal platelet production, and marked thrombocytosis in peripheral blood, and exclusion of secondary/reactive thrombocytosis (s 7(2)(a)-(b), Notes 1-3). Do not rely solely on the ICD‑10‑AM code D47.3; the SoP requires that the statutory meaning be met (ss 7(3)-(4)).

3. Document and calculate pack‑years precisely. If relying on the smoking factor, produce a clear calculation of pack‑years using the Schedule’s definition and examples (Schedule, one pack‑year and Notes 1-2). Record daily tobacco consumption (cigarettes per day), convert non‑cigarette tobacco volumes using the Schedule’s equivalence (1 gram = 1 cigarette; 7,300 grams per year equivalence), calculate total pack‑years, and document dates of commencement and cessation. Provide a worked calculation showing that the claimant has at least 10 pack‑years, commenced smoking at least 5 years before clinical onset, and, if cessation occurred, that clinical onset fell within 15 years of cessation (s 9(1)).

4. Establish clinical onset. Because “clinical onset” is the timing hinge for the smoking factor and is not defined in the SoP, arrange for clinicians to state, based on records and diagnosis timelines, the date of clinical onset. Where diagnosis was delayed, provide medical records showing symptom onset, diagnostic testing, and the clinician’s date of first clinical recognition. Precise dating is essential to meet the temporal thresholds in s 9(1) and to assess whether the management factor at s 9(2) and s 10(2) could apply.

5. If relying on inability to obtain appropriate clinical management, evidence accessibility and causal effect. For s 9(2), gather contemporaneous records demonstrating attempts to obtain treatment, refusals, limitations in local capacity, documented delays, referrals that were not acted upon, or other barriers to receiving what treating clinicians describe as “appropriate clinical management”. Because s 10(2) narrows the applicability of s 9(2) to cases where ET was suffered or contracted before or during service and did not arise out of service, also document the timing of contraction/suffering relative to service dates. Obtain medical opinions that explain how the inability to obtain appropriate management materially contributed to or aggravated the ET, as the SoP requires material contribution or aggravation (s 10(2)).